Edge Therapeutics, Inc. (EDGE) Reaches $13.96 52-Week High; Aware (AWRE)’s Sentiment Is 1.27

February 15, 2018 - By Louis Casey

The stock of Edge Therapeutics, Inc. (NASDAQ:EDGE) hit a new 52-week high and has $15.07 target or 8.00% above today’s $13.96 share price. The 8 months bullish chart indicates low risk for the $430.64M company. The 1-year high was reported on Feb, 15 by Barchart.com. If the $15.07 price target is reached, the company will be worth $34.45 million more. The stock increased 1.49% or $0.205 during the last trading session, reaching $13.955. About 74,026 shares traded. Edge Therapeutics, Inc. (NASDAQ:EDGE) has risen 23.72% since February 15, 2017 and is uptrending. It has outperformed by 7.02% the S&P500.

Aware, Inc. provides software and services for the biometrics industry worldwide. The company has market cap of $95.10 million. The companyÂ’s software products are used in government and commercial biometrics systems to identify or authenticate people. It has a 44.44 P/E ratio. It offers biometrics software products, including biometric services platform, search and match products, software development kits, and application products for fingerprint, facial, and iris modalities that enable various functions in biometrics systems, such as enrollment, analysis, and processing of biometrics images and data on workstations or mobile devices; integration of peripheral biometric capture devices; centralized workflow, transaction processing, and subsystem integration; matching of biometric samples against biometric databases to authenticate or verify identities; and analysis and processing of text identity data.

Punch & Associates Investment Management Inc. holds 0.27% of its portfolio in Aware, Inc. for 657,879 shares. Ashfield Capital Partners Llc owns 175,108 shares or 0.11% of their US portfolio. Moreover, Essex Investment Management Co Llc has 0.06% invested in the company for 87,791 shares. The Illinois-based Glenview State Bank Trust Dept. has invested 0.05% in the stock. Css Llc Il, a Illinois-based fund reported 24,737 shares.

The stock increased 1.15% or $0.05 during the last trading session, reaching $4.4. About 1 shares traded. Aware, Inc. (AWRE) has risen 14.09% since February 15, 2017 and is uptrending. It has underperformed by 2.61% the S&P500.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital therapies for acute life-threatening neurological and other conditions. The company has market cap of $430.64 million. The Company’s lead product includes EG-1962, a polymer microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. It currently has negative earnings. The firm is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain.

Analysts await Edge Therapeutics, Inc. (NASDAQ:EDGE) to report earnings on March, 1. They expect $-0.47 earnings per share, down 42.42% or $0.14 from last year’s $-0.33 per share. After $-0.37 actual earnings per share reported by Edge Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 27.03% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>